Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Correction to Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase.

Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS.

J Med Chem. 2017 Apr 13;60(7):3219. doi: 10.1021/acs.jmedchem.7b00427. Epub 2017 Mar 24. No abstract available.

PMID:
28339203
2.

Molecular and structural basis for the roles of hepatitis C virus polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance.

Lam AM, Edwards TE, Mosley RT, Murakami E, Bansal S, Lugo C, Bao H, Otto MJ, Sofia MJ, Furman PA.

Antimicrob Agents Chemother. 2014 Nov;58(11):6861-9. doi: 10.1128/AAC.03847-14. Epub 2014 Sep 2.

3.

Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives.

Kakarla R, Liu J, Naduthambi D, Chang W, Mosley RT, Bao D, Steuer HM, Keilman M, Bansal S, Lam AM, Seibel W, Neilson S, Furman PA, Sofia MJ.

J Med Chem. 2014 Mar 13;57(5):2136-60. doi: 10.1021/jm4012643. Epub 2014 Jan 29.

PMID:
24476391
4.

Use of 2'-spirocyclic ethers in HCV nucleoside design.

Du J, Chun BK, Mosley RT, Bansal S, Bao H, Espiritu C, Lam AM, Murakami E, Niu C, Micolochick Steuer HM, Furman PA, Sofia MJ.

J Med Chem. 2014 Mar 13;57(5):1826-35. doi: 10.1021/jm401224y. Epub 2013 Oct 18.

PMID:
24079820
5.

β-D-2'-α-F-2'-β-C-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study.

Du J, Bao D, Chun BK, Jiang Y, Reddy PG, Zhang HR, Ross BS, Bansal S, Bao H, Espiritu C, Lam AM, Murakami E, Niu C, Micolochick Steuer HM, Furman PA, Otto MJ, Sofia MJ.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5924-9. doi: 10.1016/j.bmcl.2012.07.066. Epub 2012 Jul 27.

PMID:
22892115
6.

Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938.

Niu C, Tolstykh T, Bao H, Park Y, Babusis D, Lam AM, Bansal S, Du J, Chang W, Reddy PG, Zhang HR, Woolley J, Wang LQ, Chao PB, Ray AS, Otto MJ, Sofia MJ, Furman PA, Murakami E.

Antimicrob Agents Chemother. 2012 Jul;56(7):3767-75. doi: 10.1128/AAC.00530-12. Epub 2012 Apr 23.

7.

Structure of hepatitis C virus polymerase in complex with primer-template RNA.

Mosley RT, Edwards TE, Murakami E, Lam AM, Grice RL, Du J, Sofia MJ, Furman PA, Otto MJ.

J Virol. 2012 Jun;86(12):6503-11. doi: 10.1128/JVI.00386-12. Epub 2012 Apr 11.

8.

A 2'-deoxy-2'-fluoro-2'-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase.

Liu J, Du J, Wang P, Nagarathnam D, Espiritu CL, Bao H, Murakami E, Furman PA, Sofia MJ.

Nucleosides Nucleotides Nucleic Acids. 2012 Apr;31(4):277-85. doi: 10.1080/15257770.2012.658131.

PMID:
22444190
9.

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.

Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. doi: 10.1128/AAC.00054-12. Epub 2012 Mar 19.

10.

Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics.

Chang W, Mosley RT, Bansal S, Keilman M, Lam AM, Furman PA, Otto MJ, Sofia MJ.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2938-42. doi: 10.1016/j.bmcl.2012.02.051. Epub 2012 Feb 28.

PMID:
22425564
11.

Phosphoramidate prodrugs of (-)-β-D-(2R,4R)-dioxolane-thymine (DOT) as potent anti-HIV agents.

Wang P, Rachakonda S, Zennou V, Keilman M, Niu C, Bao D, Ross BS, Furman PA, Otto MJ, Sofia MJ.

Antivir Chem Chemother. 2012 May 14;22(5):217-38. doi: 10.3851/IMP2079.

PMID:
22358223
12.

Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.

Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS.

J Med Chem. 2012 Mar 22;55(6):2481-531. doi: 10.1021/jm201384j. Epub 2012 Jan 23. Review. No abstract available. Erratum in: J Med Chem. 2017 Apr 13;60(7):3219.

PMID:
22185586
13.

Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.

Chun BK, Du J, Zhang HR, Chang W, Ross BS, Jiang Y, Bao D, Espiritu CL, Keilman M, Steuer HM, Furman PA, Sofia MJ.

Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):886-96. doi: 10.1080/15257770.2011.614308.

PMID:
22060553
14.

Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.

Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Zennou V, Otto MJ, Furman PA.

J Virol. 2011 Dec;85(23):12334-42. doi: 10.1128/JVI.05639-11. Epub 2011 Sep 28.

15.

Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)- or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates.

Murakami E, Bao H, Mosley RT, Du J, Sofia MJ, Furman PA.

J Med Chem. 2011 Aug 25;54(16):5902-14. doi: 10.1021/jm200650j. Epub 2011 Jul 22.

PMID:
21755941
16.

Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs.

Wang P, Naduthambi D, Mosley RT, Niu C, Furman PA, Otto MJ, Sofia MJ.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4642-7. doi: 10.1016/j.bmcl.2011.05.077. Epub 2011 Jun 6.

PMID:
21704526
17.

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.

Furman PA, Murakami E, Niu C, Lam AM, Espiritu C, Bansal S, Bao H, Tolstykh T, Micolochick Steuer H, Keilman M, Zennou V, Bourne N, Veselenak RL, Chang W, Ross BS, Du J, Otto MJ, Sofia MJ.

Antiviral Res. 2011 Aug;91(2):120-32. doi: 10.1016/j.antiviral.2011.05.003. Epub 2011 May 12.

18.

Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.

Lam AM, Espiritu C, Murakami E, Zennou V, Bansal S, Micolochick Steuer HM, Niu C, Keilman M, Bao H, Bourne N, Veselenak RL, Reddy PG, Chang W, Du J, Nagarathnam D, Sofia MJ, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2011 Jun;55(6):2566-75. doi: 10.1128/AAC.00032-11. Epub 2011 Mar 28.

19.

Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection.

Chang W, Bao D, Chun BK, Naduthambi D, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Zhang HR, Bansal S, Espiritu CL, Keilman M, Lam AM, Niu C, Steuer HM, Furman PA, Otto MJ, Sofia MJ.

ACS Med Chem Lett. 2010 Dec 17;2(2):130-5. doi: 10.1021/ml100209f. eCollection 2011 Feb 10.

20.

2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938.

Reddy PG, Bao D, Chang W, Chun BK, Du J, Nagarathnam D, Rachakonda S, Ross BS, Zhang HR, Bansal S, Espiritu CL, Keilman M, Lam AM, Niu C, Steuer HM, Furman PA, Otto MJ, Sofia MJ.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7376-80. doi: 10.1016/j.bmcl.2010.10.035. Epub 2010 Oct 15.

PMID:
21050754
21.

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA.

J Med Chem. 2010 Oct 14;53(19):7202-18. doi: 10.1021/jm100863x.

PMID:
20845908
22.

Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.

Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA.

J Biol Chem. 2010 Nov 5;285(45):34337-47. doi: 10.1074/jbc.M110.161802. Epub 2010 Aug 26.

23.

Synthesis and anti-HCV activity of 3',4'-oxetane nucleosides.

Chang W, Du J, Rachakonda S, Ross BS, Convers-Reignier S, Yau WT, Pons JF, Murakami E, Bao H, Steuer HM, Furman PA, Otto MJ, Sofia MJ.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4539-43. doi: 10.1016/j.bmcl.2010.06.025. Epub 2010 Jun 8.

PMID:
20580554
24.

Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.

Niu C, Bao H, Tolstykh T, Micolochick Steuer HM, Murakami E, Korba B, Furman PA.

Antivir Ther. 2010;15(3):401-12. doi: 10.3851/IMP1541.

PMID:
20516559
25.

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.

Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG, Morrey JD, Smee DF, Frick DN, Heck JA, Wang P, Nagarathnam D, Ross BS, Sofia MJ, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2010 Aug;54(8):3187-96. doi: 10.1128/AAC.00399-10. Epub 2010 Jun 1.

26.

Development of novel therapies for hepatitis C.

Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA.

Antiviral Res. 2010 Apr;86(1):79-92. doi: 10.1016/j.antiviral.2010.02.003. Review.

PMID:
20417376
27.

Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.

Furman PA, Lam AM, Murakami E.

Future Med Chem. 2009 Nov;1(8):1429-52. doi: 10.4155/fmc.09.88. Review.

PMID:
21426058
28.
29.

The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2008 Feb;52(2):458-64. Epub 2007 Nov 12.

30.

Mechanism of action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl) thymine as an anti-HIV agent.

Murakami E, Bao H, Basavapathruni A, Bailey CM, Du J, Steuer HM, Niu C, Whitaker T, Anderson KS, Otto MJ, Furman PA.

Antivir Chem Chemother. 2007;18(2):83-92.

PMID:
17542153
31.

Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.

Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA.

Antimicrob Agents Chemother. 2007 Feb;51(2):503-9. Epub 2006 Nov 13.

32.

Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ.

Antivir Chem Chemother. 2006;17(2):79-87.

PMID:
17042329
33.

Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.

Korba BE, Furman PA, Otto MJ.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):549-61. Review.

PMID:
17009935
34.

Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.

Clark JL, Mason JC, Hollecker L, Stuyver LJ, Tharnish PM, McBrayer TR, Otto MJ, Furman PA, Schinazi RF, Watanabe KA.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1712-5. Epub 2005 Dec 20.

PMID:
16368235
35.

Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides.

Hocek M, Naus P, Pohl R, Votruba I, Furman PA, Tharnish PM, Otto MJ.

J Med Chem. 2005 Sep 8;48(18):5869-73.

PMID:
16134952
36.

Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.

Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman PA, Stec WJ, Patterson SE, Pankiewicz KW.

J Med Chem. 2005 Aug 25;48(17):5504-8.

PMID:
16107149
38.

Synthesis and evaluation of a novel synthetic phosphocholine lipid-AZT conjugate that double-targets wild-type and drug resistant variants of HIV.

Kucera LS, Morris-Natschke SL, Ishaq KS, Hes J, Iyer N, Furman PA, Fleming RA.

Nucleosides Nucleotides Nucleic Acids. 2004;23(1-2):385-99.

PMID:
15043162
39.
40.

Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.

Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Cable EE, Isom HC.

Antimicrob Agents Chemother. 2003 Jan;47(1):324-36.

41.

Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach.

Chong Y, Borroto-Esoda K, Furman PA, Schinazi RF, Chu CK.

Antivir Chem Chemother. 2002 Mar;13(2):115-28.

PMID:
12238529
42.

Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment.

Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Isom HC.

J Virol. 2002 Aug;76(16):8148-60.

43.

Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.

Furman PA, Jeffrey J, Kiefer LL, Feng JY, Anderson KS, Borroto-Esoda K, Hill E, Copeland WC, Chu CK, Sommadossi JP, Liberman I, Schinazi RF, Painter GR.

Antimicrob Agents Chemother. 2001 Jan;45(1):158-65.

44.

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS.

J Virol. 2001 Jan;75(1):311-22.

45.
46.

Conformation and local environment of nucleotides bound to HIV type 1 reverse transcriptase (HIV-1 RT) in the ground state.

Painter GR, Andrews CW, Furman PA.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):13-29.

PMID:
10772700
47.

Screening for potential toxicity of antiviral therapies.

Szczech GM, Furman PA.

Curr Opin Drug Discov Devel. 2000 Jan;3(1):56-62.

PMID:
19649838
48.

The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl. Acad. Sci. USA 74, 5716-5720 (1977)

Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ.

Rev Med Virol. 1999 Jul;9(3):147-52; discussion 152-3. No abstract available.

PMID:
10479776
49.

Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5'-triphosphate.

Wilson JE, Aulabaugh A, Caligan B, McPherson S, Wakefield JK, Jablonski S, Morrow CD, Reardon JE, Furman PA.

J Biol Chem. 1996 Jun 7;271(23):13656-62.

50.

Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous.

Wilson JE, Wright LL, Martin JL, Haire SE, Ray PH, Painter GR, Furman PA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):20-30.

PMID:
8528729

Supplemental Content

Loading ...
Support Center